X0306 4 2022-03-04 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001722360 Stark David Matthew C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL 0 1 0 0 Exec. VP Chief Legal Officer Ordinary Shares 2022-03-04 4 M 0 37939 A 59319.39 D Ordinary Shares 2022-03-04 4 S 0 17008 7.4825 D 42311.39 D Ordinary Shares 2022-03-04 4 M 0 13930 A 56241.39 D Ordinary Shares 2022-03-04 4 S 0 6246 7.4825 D 49995.39 D Ordinary Shares 2022-03-05 4 M 0 20199 A 70194.39 D Ordinary Shares 2022-03-07 4 S 0 9057 7.3667 D 61137.39 D Restricted Share Units 2022-03-04 4 M 0 37939 0.00 D Ordinary Shares 37939 0 D Restricted Share Units 2022-03-04 4 M 0 13930 0.00 D Ordinary Shares 13930 13931 D Restricted Share Units 2022-03-04 4 A 0 127345 0.00 A Ordinary Shares 127345 127345 D Restricted Share Units 2022-03-05 4 M 0 20199 0.00 D Ordinary Shares 20199 60599 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023. Restricted share units were granted on March 4, 2022, with 31,836 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 31,837 vesting on March 4, 2026. Restricted share units were granted on March 5, 2021, with 20,199 having vested on March 5, 2022, 20,199 vesting on each of March 5, 2023 and March 5, 2024, and 20,201 vesting on March 5, 2025. /s/ Dov Bergwerk as attorney-in-fact for David M. Stark 2022-03-08